Company intelligence / Profile preview

MacuLogix

Middletown, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

MacuLogix developed and commercialized the FDA‑cleared AdaptDx and AdaptDx Pro dark adaptometer devices, which measure dark adaptation as an early functional biomarker to detect and monitor age-related macular degeneration in clinical practice.[1][4] Over 1 million tests have been performed and about 200,000 patients diagnosed using the AdaptDx platform.[1]

Therapeutic areas: Ophthalmology
Modalities: DeviceNon-pharmacological therapy
Industry: Physiological Monitoring

Partnerships

LumiThera (asset acquisition and integration of AdaptDx Pro into LumiThera’s diagnostic and treatment platform for dry age-related macular degeneration)[1]

Beyond the preview

Go deeper on MacuLogix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MacuLogix.

Explore the full profile